Sarepta price target lowered to $151 from $155 at RBC Capital

RBC Capital lowered the firm’s price target on Sarepta to $151 from $155 but keeps an Outperform rating on the shares. The key value driver for shares going forward will be progress toward the multibillion-dollar opportunity for Sarepta’s two most advanced muscular dystrophy gene therapy programs, and based on the robust expression, biomarker and safety data for both programs to date, along with highly encouraging functional gains, Sarepta could have the best-in-class therapy for both Duchenne and limb girdle muscular dystrophy, the analyst tells investors in a research note.